On April 29, 2021 Scandion Oncology reported that Annual Report 2020 has now been published and is available on the company’s website (www.scandiononcology.com ) (Press release, Scandion Oncology, APR 29, 2021, View Source;scandion-oncology-is-setting-the-pace-for-the-future,c3336417 [SID1234578868]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Bo Rode Hansen, President & CEO, Scandion Oncology A/S comments:

"In 2020, we met major catalysts with initiation of clinical trials, securing financing, preparing for list change to Nasdaq and internationalization. We saw the first signs of activity with SCO-101 and FOLFIRI in patients. This enabled the company to secure a strong financial position and start building the organization for the future.

In 2021, we are expecting the first conclusive data to read out from our CORIST study in Q2. We will use the results from the CORIST study together with a new international positioning analysis of the broader commercial platform potential for Scandion Oncology to focus our clinical strategies going ahead.

We will continue to focus on value for patients and shareholders on our journey towards building the Cancer Drug Resistance Company."